Shire, Impax End Suit Over Supplies For Authorized Generic of Adderall XR

Impax Laboratories Inc. and Shire LLC have settled all pending litigation relating to Shire’s obligations to supply Impax with authorized generic Adderall XR pursuant to the parties’ 2006 license and distribution agreement, the companies announced Feb. 8.

Adderall XR (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules) is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

As a condition of settlement, Shire will make a one-time $48 million cash payment to Impax.

Impax began to sell authorized generic Adderall XR in October 2009. An authorized generic drug is a branded prescription drug produced ...